Cord Blood News Volume 4.20 | May 24 2012

Proteomic Validation of Multifunctional Molecules in Mesenchymal Stem Cells Derived from Human Bone Marrow, Umbilical Cord Blood and Peripheral Blood
To understand the different molecular conditions that govern the different application or differentiation potential of each mesenchymal stem cell (MSC) according to cellular source, scientists generated a proteome reference map of MSCs obtained from bone marrow, umbilical cord blood and peripheral blood. [PLoS One] Full Article

Bmi1 Confers Resistance to Oxidative Stress on Hematopoietic Stem Cells
Researchers demonstrated that overexpression of Bmi1 confers resistance to stresses, particularly oxidative stress, onto hematopoietic stem cells. [PLoS One] Full Article

Irradiated Allogeneic Cells Enhance Umbilical Cord Blood Stem Cell Engraftment in Immunodeficient Mice
Researchers performed experiments to determine if adjunctive therapy with third-party human allogeneic cells enhances the engraftment of human umbilical cord blood in immunodeficient mice. [Bone Marrow Transplant] Abstract

Beneficial Effects of Non-Matched Allogeneic Cord Blood Mononuclear Cells upon Patients with Idiopathic Osteoporosis
To study the benefit of blood mononuclear cell therapy, eight patients with idiopathic osteoporosis were given intermittent treatments with non-matched allogeneic cord blood mononuclear cells for three months. [J Transl Med] Full Article

Cryopreservation of Human Vascular Umbilical Cord Cells Under Good Manufacturing Practice Conditions for Future Cell Banks
Human umbilical cord artery derived cells and human umbilical vein endothelial cells were isolated, cultivated, cryopreserved directly after primary culture and recultivated subsequently. Cell viability, expression of cellular markers and proliferation potential of fresh and cryopreserved cells were studied using trypan blue staining, flow cytometry analysis, immunofluorescence staining and proliferation assays. [J Transl Med] Full Article

Optimizing Megakaryocyte Polyploidization by Targeting Multiple Pathways of Cytokinesis
Megakaryocytes were derived from umbilical cord blood and cultured with reagents that inhibit distinct mechanisms of cytokinesis. Combinations of reagents were used to determine their interactions and to maximize megakaryocyte ploidy. [Transfusion] Abstract

The Prevalence of Intracellular Galectin-1-Expressing Lymphocytes in Umbilical Cord Blood in Comparison with Adult Peripheral Blood
Investigators aimed to determine the properties of intracellular galectin-1-producing cells within CD3, CD4, CD8, regulatory T and NK cells in umbilical cord blood compared to adult peripheral blood. [Biol Blood Marrow Transplant] Abstract

Candidate Biomarkers for Acute Rejection of Pregnancy after In Utero Cell-Based Therapy in Pre-Immune Embryos via Ultrasound-Guided Celocentesis
The maternal serum concentrations of nine candidate biomarkers for acute rejection of pregnancy were determined before and after the injection of different cocktails of human umbilical cord blood stem cells into the gestational sac. [Am J Reprod Immunol] Abstract

World’s First Approved Stem Cell Drug; Osiris Receives Marketing Clearance from Health Canada for Prochymal
Osiris Therapeutics Inc. announced that it has received market authorization from Health Canada to market its stem cell therapy Prochymal^® (remestemcel-L) for the treatment of acute graft-vs-host disease in children. [Osiris Therapeutics, Inc.] Press Release

ThermoGenesis Announces AXP Approval in Thailand
ThermoGenesis Corp. said that it received regulatory approval in Thailand for its AXP^® AutoXpress^® Platform (AXP) used for the processing of cord blood. [ThermoGenesis Corp.] Press Release

IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
IntelliCell BioSciences, Inc. announced that it has entered a sponsored research agreement with the Institute for Cell Engineering and Regenerative Medicine at the University of Florida. [PR Newswire] Press Release

Maryland Stem Cell Research Commission Funds 40 New Proposals in FY 2012
The board of directors of the Maryland Technology Development Corporation approved the Commission’s recommendation to fund 40 new proposals with the Maryland Stem Cell Research Fund’s $12.4 million FY 2012 budget. [Maryland Stem Cell Research Fund] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Scientist – hPSC Bioengineering (STEMCELL Technologies, Inc.)

Scientist – Antibody and Hybridoma Technology Platforms (STEMCELL Technologies, Inc.)

Scientist – Epithelial Cell Research (STEMCELL Technologies, Inc.)

Scientist – Induced Pluripotent Stem Cells (STEMCELL Technologies, Inc.)

Scientist – Endothelial Cells (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Research Associate – Chemistry (STEMCELL Technologies, Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies, Inc.)

Research Technologist – Contract Assay Services (STEMCELL Technologies, Inc.)

Business Analyst – Product Management (STEMSOFT Software, Inc.)

Business Development Manager – Stem Cell (SynGen Inc.)

Controller (SynGen Inc.)

Director: Regulatory Affairs (SynGen Inc.)

Manufacturing Manager (SynGen Inc.)

Chief Scientific Officer (SynGen Inc.)

Development Scientist – Cell Therapy (GE Healthcare)

Group Leaders, Principle Scientists – Stem Cell Clinical Product R&D (Shanghai Hengrui Pharmaceuticals Co., Ltd)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.